An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study

Eldem, Bora; Lai, Timothy; Ngah, Nor; Vote, Brendan; Yu, Hyeong; Fabre, Alban; Backer, Arthur; Clunas, Nathan

doi:10.1007/s00417-017-3890-8

An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study

Eldem B., Lai T. Y. Y., Ngah N. F., Vote B., Yu H. G., Fabre A., ...Daha Fazla

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, cilt.256, sa.5, ss.963-973, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 256 Sayı: 5
Basım Tarihi: 2018
Doi Numarası: 10.1007/s00417-017-3890-8
Dergi Adı: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.963-973
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

To describe intravitreal ranibizumab treatment frequency, clinical monitoring, and visual outcomes (including mean central retinal thickness [CRT] and visual acuity [VA] changes from baseline) in neovascular age-related macular degeneration (nAMD) in real-world settings across three ranibizumab reimbursement scenarios in the Middle East, North Africa, and the Asia-Pacific region.